Dirk‐Thomas Waldschmidt
Impact in
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Hepatocellular Carcinoma Treatment and Prognosis 6
- Oncology 3
- Pancreatic and Hepatic Oncology Research 2
- Cancer Immunotherapy and Biomarkers 1
- Co-authors
- Tim Meyer (1 shared paper)Donatella Marino (1 shared paper)Stefan Hubert Boeck (1 shared paper)Antonio Gasbarrini (1 shared paper)José Presa (1 shared paper)Uwe Pelzer (1 shared paper)Lipika Goyal (1 shared paper)Joycelyn Jie Xin Lee (1 shared paper)
- Journals
- Liver Cancer (3 papers)Journal of Hepatology (2 papers)JCO Precision Oncology (1 paper)JHEP Reports (1 paper)The Lancet. Gastroenterology & hepatology (1 paper)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Dirk‐Thomas Waldschmidt
9 papers receiving 1.6k citations
Dirk‐Thomas Waldschmidt's Hit Papers
Peers
Comparison fields: 5 of 62
- Hepatology 877
- Oncology 335
- Epidemiology 207
- Cancer Research 85
- Surgery 230
Countries citing papers authored by Dirk‐Thomas Waldschmidt
This map shows the geographic impact of Dirk‐Thomas Waldschmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk‐Thomas Waldschmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk‐Thomas Waldschmidt more than expected).
Fields of papers citing papers by Dirk‐Thomas Waldschmidt
This network shows the impact of papers produced by Dirk‐Thomas Waldschmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk‐Thomas Waldschmidt. The network helps show where Dirk‐Thomas Waldschmidt may publish in the future.
Co-authors
The 25 scholars most cited alongside Dirk‐Thomas Waldschmidt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | NASH limits anti-tumour surveillance in immunotherapy-treated HCC Hit paper breakdown → | 2021 | 1029 |
| 2 | Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study Hit paper breakdown → | 2021 | 341 |
| 3 | Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score Hit paper breakdown → | 2021 | 230 |
| 4 | 2021 | 32 | |
| 5 | 2024 | 8 | |
| 6 | 2023 | 3 | |
| 7 | 2024 | 3 | |
| 8 | 2018 | 1 | |
| 9 | 2025 | 1 | |
| 10 | 2024 | 0 | |
| 11 | 2026 | 0 |
About Dirk‐Thomas Waldschmidt
Dirk‐Thomas Waldschmidt is a scholar working on Hepatology, Oncology, Surgery, Nuclear Energy and Engineering and Waste Management and Disposal, having authored 11 papers that have together received 1.6k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Cancer Immunotherapy and Biomarkers (1 paper). The work is most often cited by research in Hepatology (877 citations), Oncology (335 citations), Epidemiology (207 citations), Cancer Research (85 citations) and Surgery (230 citations). Dirk‐Thomas Waldschmidt has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Tim Meyer, Donatella Marino, Stefan Hubert Boeck, Antonio Gasbarrini, José Presa, Uwe Pelzer, Lipika Goyal, Joycelyn Jie Xin Lee, Sabine Merkelbach‐Bruse and Arndt Weinmann. Their work appears in journals such as Liver Cancer, Journal of Hepatology, JCO Precision Oncology, JHEP Reports and The Lancet. Gastroenterology & hepatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.